German spray pump manufacturer Aero Pump and soft mist inhaler developer Resyca have announced a partnership for the development and launch of a device called the Ultra Soft Nasal Pump Spray, which is now available for licensing. In January 2024, Resyca parent companies Recipharm (now Bespak) and Medspray announced that they had added development of soft mist nasal devices to their original partnership that launched Resyca as a joint venture to develop SMIs based on Medspray’s nozzle technology.
According to the announcement, the new nasal delivery platform is designed for delivery of CNS drugs to the brain and can also be used for intranasal vaccines. The companies say that the pump can be filled aseptically and is suitable for multidose nasal sprays.
Resyca CEO Remko Beimers commented, “We are excited to bring this groundbreaking device to market. By combining Resyca’s expertise in soft mist drug delivery technology with Aero Pump’s experience in commercializing nasal spray devices, the Ultra Soft Nasal Spray Pump sets a new benchmark in nasal drug delivery.”
Aero Pump General Manager Stefan Christ said, “This collaboration is a testament to the innovation driving our industry forward. Together with Resyca, we offer an unmatched solution for nasal drug delivery, from device design to full regulatory support, making it easier for pharmaceutical companies to bring advanced treatments to market.”
Read the Resyca press release.
